The Science Behind Dermikelp®
Dermikelp® has been in ongoing research and development since 2009, and has been on the market since 2011. As part of our ongoing research and development, we partnered with dermatologists in the EU to test the safety of Dermikelp® using a test known as a Human Repeat Insult Patch Test (HRIPT). The results of these tests conclusively determined that Dermikelp® products will not cause further irritation to existing skin conditions.
Satisfied with the safety of our products, the next step was to put Dermikelp® through clinical trials to determine product efficacy. The results of these trials proved that Dermikelp® offers relief that is comparable to 1% hydrocortisone creams within 30 minutes from application, but without any of the associated side effects. What this means is that Dermikelp® is effective in rapidly relieving the symptoms associated with irritated, inflamed and itchy skin, and assists in breaking the itch-scratch cycle (when itching is so severe that it is impossible to resist scratching, which then ultimately irritates the skin further and leads to even more inflammation and itching).
Research conducted at University of the Western Cape showed that our CEM-K yielded higher concentrations of compounds that have known health benefits including anti-inflammatory and anti-viral properties.
In testing conducted by Dermatologists in the European Union, Dermikelp® Cream (containing the CEM-K active ingredient) showed a reduction in the rate of erythema (redness & inflammation) in skin as follows:
Dermatologists in Europe